Daily News

White House Holds Up Azar’s Generic Drug Advocacy Amidst Criticisms Over HHS Nominee’s Drug Pricing Comments

November 13, 2017
The White House is holding up HHS Secretary nominee Alex Azar’s advocacy for generic drug competition as evidence that he will, as President Donald Trump promised, rein in high drug prices. Trump, in a tweet announcing the HHS nomination, said Azar, an HHS veteran and former executive at Lilly, “will be a star for better healthcare and lower drug prices.” Industry critic Public Citizen quickly pounced on Azar, alleging “he is opposed to measures to restrain prescription companies’ profiteering and...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, news from FDA and much more.